Drug Approval | May 10, 2024
Alembic Pharmaceuticals receives 5 USFDA product approvals in Q1 FY25
Receives 3 final and 2 tentative product approvals thus far in Q1FY25
Receives 3 final and 2 tentative product approvals thus far in Q1FY25
The company has posted net profit of Rs. 1,201.22 crores for the Financial Year ended March 31, 2024
The company has posted net profit of Rs.8.29 crores for the Financial Year ended March 31, 2024
The company has posted net profit of Rs.615.82 crores for the Financial Year ended March 31, 2024
The company has posted net profit of Rs.118.82 crores for the Financial Year ended March 31, 2024
The company has posted net profit of Rs.171.42 crores for the Financial Year ended March 31, 2024
The company has posted net loss of Rs. 105.07 crores for the Financial Year ended March 31, 2024
The company has posted net profit of Rs.30.35 crores for the Financial Year ended March 31, 2024
The company has reported total income of Rs. 155.79 crores during the period ended March 31, 2024
The company has reported total income of Rs. 2,943.49 crores during the period ended March 31, 2024
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
